Skip to main content
Mark Collins, MD, Oncology, Wilmington, OH

MarkCollinsMD

Oncology Wilmington, OH

Ohio State CCC/The James

Dr. Collins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Collins' full profile

Already have an account?

  • Office

    31 Farquhar Ave
    PO Box 600
    Wilmington, OH 45177
    Phone+1 937-283-2273
    Fax+1 937-283-2278

Education & Training

  • San Antonio Uniformed Services Health Education Consortium
    San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1983 - 1986
  • UniforMed Services University of the Health Sciences F. Edward Hebert School of Medicine
    UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1983

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1993 - 2025
  • NJ State Medical License
    NJ State Medical License 1988 - 1993
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012

Press Mentions

  • Predictive Oncology’s (NASDAQ: POAI) Helomics Exec Talks AI, Big Data and Biology During Podcast Appearance - NetworkNewsWire
    Predictive Oncology’s (NASDAQ: POAI) Helomics Exec Talks AI, Big Data and Biology During Podcast Appearance - NetworkNewsWireMarch 29th, 2021
  • Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options
    Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment OptionsJanuary 28th, 2021
  • Predictive Oncology: Helomics to Present Initial Findings from Its Analysis of UK 100,000 Genomes Project Data Towards Its Goal of Building AI-Driven Predictive Models of Ovarian Cancer
    Predictive Oncology: Helomics to Present Initial Findings from Its Analysis of UK 100,000 Genomes Project Data Towards Its Goal of Building AI-Driven Predictive Models of Ovarian CancerOctober 24th, 2019
  • Join now to see all

Professional Memberships